Thanks, walldiver. The iBox has been updated with a pointer to the latest revision.
If you get a chance, it would be nice to add an entry in the file for the insider holdings including the recent open-market purchases. Insider buying is not that common in the biotech world, so it’s worth highlighting, IMO.
9901 trial Gleason score breakdown (we now know that 4 out of 5 surviving placebo arm patients crossed over to receive salvage Provenge after progression) http://tinyurl.com/5v6xy
Biotech Monthly has the most comprehensive background info for Dendreon, far more than any brokerage house. The Nov 2004 issue would be available for a single-issue purchase, approx 40 pages are devoted to Dendreon. Price for single issue is in the $100 range. The issue covers the Provenge mechanism of action, trial history, and pipeline. http://www.biotechMonthly.com/archive_2004.htm